Evidence map›Paper›PMID 40901718›Full record

ArticleJournal of neuropathology and experimental neurology2026

A fixed brain seeded amplification assay to complement neuropathological prion disease diagnosis.

Victoria Lewis, Laura Ellett, Enie Lei, Christiane Stehmann, Ian Birchall, Matteo Senesi, Catriona McLean, Steven J Collins

Abstract read
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victoria LewisDepartment of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia.
Laura EllettThe Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Enie LeiThe Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Christiane StehmannAustralian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Ian BirchallThe Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Matteo SenesiDepartment of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia.
Catriona McLeanThe Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Steven J CollinsDepartment of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia.

Funding

Australian Government Department of HealthAustralian Government Department of Health, Disability and AgeingAustralian National Creutzfeldt-JakobDisability and AgeingThe Australian National Creutzfeldt-Jakob Disease Registry
6 · The paper itself

Abstract

Prion diseases are rare neurodegenerative disorders that share misfolding of the normal cellular prion protein into disease-causing isoforms known as "prions" as the critical pathophysiological event. Definite diagnosis can only be achieved through neuropathological confirmation. The neuropathological features of prion disease are well described; however, some molecular subtypes are typified by characteristic neuropathological features that are subtle or absent. Prion seeding assays have excellent specificity and have considerably improved premortem diagnostic accuracy but they have reduced sensitivity for some uncommon prion disease molecular subtypes. We developed a formalin-fixed, paraffin-embedded tissue-based prion seeding assay to serve as a complementary diagnostic tool for prion diseases. Fixed brain tissue was prepared through an optimized process involving careful defacing of tissue blocks prior to sampling and then stepwise deparaffinization and homogenization. Fixed tissue homogenates are then tested in an adapted version of a diagnostic cerebrospinal fluid (CSF) prion seeding assay, which utilizes full-length recombinant hamster prion protein as substrate. Two examples illustrate the utility of the assay by confirming prion seeding in fixed brain tissue from previously neuropathologically misdiagnosed obligate carriers of 2 different prion protein gene mutations. The importance of careful tissue sampling to rigorously maintain the diagnostic specificity of this assay is also highlighted.

Indexed as

BrainPrion DiseasesPrionsAnimalsCricetinaeHumansTissue FixationPrionsformalin-fixed paraffin-embeddedprionprion seedingPrPPrPScRT-QuIC

Identifiers

PMID40901718
PMCPMC12744881

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.